Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terconazole SCHEMBL7601910 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL18258318 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL23165 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4924542 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL5008913 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL17493426 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL4923831 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL9043676 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL6233263 | 0.94 | CYP3A4 (0.89) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| Terconazole SCHEMBL1066299 | 0.94 | CYP3A4 (0.89) | CYP3A4LMNACYP51A1FYNNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| EP-4069690-B1 | POLYMORPHS OF TRIAZOLE ANTIFUNGAL COMPOUND PC945 | PULMOCIDE LTD (GB) | 2024-11-13 | — | — | EP | claimed |
| WO-2024124117-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-06-13 | — | — | WO | claimed |
| EP-3609493-B1 | FURAZIDIN FOR THE TREATMENT OF A BACTERIAL VAGINAL INFECTION CAUSED BY GARDNERELLA VAGINALIS OR ATOPIUM VAGINAE | ADAMED PHARMA S A (PL) | 2024-05-15 | — | — | EP | claimed |
| EP-3529359-B1 | TUMOR INFILTRATING LYMPHOCYTES FOR USE IN THERAPY | UNIV MINNESOTA (US) | 2023-12-13 | — | — | EP | claimed |
| EP-2970369-B1 | CHOLESTOSOME VESICLES FOR INCORPORATION OF MOLECULES INTO CHYLOMICRONS | THERASYN SENSORS INC (US) | 2023-11-22 | — | — | EP | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-2916820-B1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL TECH LLC (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022214855-A1 | USE OF NITAZOXANIDE TO PREPARE A MEDICINAL PRODUCT TO PREVENT OR TREAT CORONAVIRUS SARS-COV-2 INFECTION | SIEGFRIED RHEIN, S.A. DE C.V. (MX) | 2022-10-13 | — | — | WO | claimed |
| EP-2437684-B1 | ANTERIOR SEGMENT DRUG DELIVERY | FORSIGHT VISION5 INC (US) | 2022-06-15 | — | — | EP | claimed |
| WO-2022047375-A1 | NOVEL FUNGAL MODULATORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2022047375-A1 | NOVEL FUNGAL MODULATORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | CYP3A4 1122/4885LMNA 2698/4885CYP51A1 802/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | CYP3A4 1150/4885LMNA 2305/4885CYP51A1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.